APA (7th ed.) Citation

MY, K., R, T., F, Y., VL, T., AL, C., & H, H. (2025). Socioeconomic Disparities in Intravitreal Injection Use and Anti-VEGF Agent Selection: Aflibercept/Ranibizumab Versus Bevacizumab. Clinical therapeutics, 47(8), 559. https://doi.org/10.1016/j.clinthera.2025.04.010

Chicago Style (17th ed.) Citation

MY, Ko, Talebi R, Yu F, Tseng VL, Coleman AL, and Hosseini H. "Socioeconomic Disparities in Intravitreal Injection Use and Anti-VEGF Agent Selection: Aflibercept/Ranibizumab Versus Bevacizumab." Clinical Therapeutics 47, no. 8 (2025): 559. https://doi.org/10.1016/j.clinthera.2025.04.010.

MLA (9th ed.) Citation

MY, Ko, et al. "Socioeconomic Disparities in Intravitreal Injection Use and Anti-VEGF Agent Selection: Aflibercept/Ranibizumab Versus Bevacizumab." Clinical Therapeutics, vol. 47, no. 8, 2025, p. 559, https://doi.org/10.1016/j.clinthera.2025.04.010.